Oral GLP-1 weight loss pills could replace injections by March 2026 at $150 monthly, Medicare chief Dr. Mehmet Oz predicted ...

Novo Nordisk has partnered with India's Emcure Pharmaceuticals to exclusively distribute and market its weight-loss drug ...

Novo Nordisk’s oral semaglutide 25 mg achieved up to 16.6% weight loss in a landmark study, rivaling injectable Wegovy. The ...

Eli Lilly and Company announced promising results for its next-generation weight-loss drug Thursday, with patients losing up ...

President Donald Trump hailed his deal to slash the price of blockbuster weight loss drugs as a game changer, promising to ...

The deal, with Eli Lilly and Novo Nordisk, is expected to lower the price of obesity drugs to between $149 and $350 per month ...

The Trump administration announced a deal with Eli Lilly and Novo Nordisk to lower the costs of GLP-1 medications, which may ...

President Donald Trump unveiled steep discounts on GLP-1 weight loss drugs in deals with pharmaceutical giants Eli Lilly and ...

Subcutaneous injections of an investigational, selective long-acting amylin receptor agonist led to clinically meaningful ...

The monthly out-of-pocket cost of popular injections and upcoming pills could range from $50 to $350, depending on the dosage ...

Dr. Oz estimated Americans could lose "135 billion pounds" by the midterm elections next year. The administrator of the ...

Emcure Pharma becomes the first Indian company to hold exclusive rights to distribute and commercialise Poviztra, a ...